Contineum Therapeutics (CTNM) Current Assets (2023 - 2026)

Contineum Therapeutics' Current Assets history runs 4 years deep, the most recent figure standing at $242.6 million for Q2 2026.

• In Q2 2026, Current Assets rose 37.18% year-over-year to $242.6 million; the TTM figure through Jun 2026 stood at $242.6 million (up 37.18% YoY), while the FY2025 annual figure was $267.9 million, up 29.81% from the prior year.
• Current Assets for Q2 2026 stood at $242.6 million, down from $253.0 million in the prior quarter.
• The five-year high for Current Assets was $267.9 million in Q4 2025, with the low at $119.7 million in Q1 2024.
• The 4-year median for Current Assets is $206.4 million (2024), against an average of $200.6 million.
• The sharpest annual moves came in 2024 and 2025: Current Assets soared 61.61% in 2024, then fell 19.74% in 2025.
• Contineum Therapeutics' Current Assets stood at $127.7 million in 2023, then jumped by 61.61% to $206.4 million in 2024, then rose by 29.81% to $267.9 million in 2025, then declined by 9.46% to $242.6 million in 2026.
• Business Quant data shows CTNM's Current Assets at $242.6 million in Q2 2026, $253.0 million in Q1 2026, and $267.9 million in Q4 2025.